Efficacy and safety of various drug combinations in treating plaque Psoriasis: A meta-analysis [version 2; peer review: 2 approved] by Nayak Snehasis, Karshe Haji Ali, Pendyala Siri, Ngabo Herve, Sayed Zafar

“…Background Psoriasis, a chronic inflammatory disease affecting the skin, joints, and nails (2-3% worldwide), significantly affects quality of life. Genetic and environmental factors also play key roles. …”
Get full text

Effects of Physical-Agent Pain Relief Modalities for Fibromyalgia Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials by Yuichiro Honda, Junya Sakamoto, Yohei Hamaue, Hideki Kataoka, Yasutaka Kondo, Ryo Sasabe, Kyo Goto, Takuya Fukushima, Satoshi Oga, Ryo Sasaki, Natsumi Tanaka, Jiro Nakano, Minoru Okita

“…The primary outcome measure was pain relief measured by a visual analogue scale (VAS), and the secondary outcome measures of interest were subjective improvements in the number of tender points, Fibromyalgia Impact Questionnaire (FIQ), and quality of life (QOL) scores. Results. Eleven studies were included in our review. …”
Get full text

Rehabilitation using virtual gaming for Hospital and hOMe-Based training for the Upper limb post Stroke (RHOMBUS II): protocol of a feasibility randomised controlled trial by Cherry Kilbride, Tom Butcher, Meriel Norris, Nana Anokye, Alyson Warland, Karen Baker, Dimitrios A Athanasiou, Guillem Singla-Buxarrais, Jennifer Ryan, Francesca Gowing, Carole Pound, Victoria Stewart, Basaam Aweid, Arul Samiyappan

“…Outcomes assessed at baseline and 7 weeks include gross level of disability, arm function, spasticity, pain, fatigue and quality of life (QoL). Safety will be assessed by recording adverse events and using pain, spasticity and fatigue scores. …”
Get full text

Comparative- and Cost-Effectiveness Research Determining the Optimal Intervention for Advancing Transgender Women With HIV to Full Viral Suppression (Text Me, Alexis!): Protocol fo... by Cathy J Reback, Thomas Blue, Ali Jalali, Raphael Landovitz, Michael J Li, Raymond P Mata, Danielle Ryan, Philip J Jeng, Sean M Murphy

“…These issues are exacerbated by comorbid conditions, such as substance use disorder, which is also associated with reduced quality of life, increased overdose deaths, usage of high-cost health care services, engagement in a street economy, and cycles of incarceration. …”
Get full text

Traditional Chinese medicine manual therapy for adolescent idiopathic scoliosis: a case report by Bowen Zhu, Miaoxiu Li, Jun Ren, Tianxiang He, Xin Zhou, Shoujian Wang, Lingjun Kong, Min Fang, Min Fang

“…Before treatment, after the first TCMMT, 1 month and 7 months of treatment, and 18 months of follow-up, we used ATR or Cobb angle and health-related quality of life (HRQOL) for assessment. The HRQOL was assessed using the visual analog scale (VAS) scores and the Scoliosis Research Society-22 (SRS-22) patient questionnaire. …”
Get full text

Spinal pain prevalence and associated determinants: A population‐based study using the National Survey for Wales by David C. Byfield, Benjamin S. Stacey, Hywel T. Evans, Ian W. Farr, Leon Yandle, Lora Roberts, Teresa Filipponi, Damian M. Bailey

“…This still represents a significant societal burden and these findings may help inform public health initiatives to encourage prevention and evidence‐based interventional strategies and ultimately, improve the quality of life for those suffering with SP in Wales.…”
Get full text

Association of social frailty, sarcopenia, and oral frailty with depressive symptoms in Chinese older adults: a cross-sectional study by Yuanhao Sun, Huan Liu, Xiangdong Li, Lin Zhang, Wenwen Xu, Hairong liu, Ting Yuan

“…This will help to improve the quality of life and mental health.…”
Get full text

Proactive and Integrated Management and Empowerment in Parkinson’s Disease: Designing a New Model of Care by Emma Tenison, Agnes Smink, Sabi Redwood, Sirwan Darweesh, Hazel Cottle, Angelika van Halteren, Pieter van den Haak, Ruth Hamlin, Jan Ypinga, Bastiaan R. Bloem, Yoav Ben-Shlomo, Marten Munneke, Emily Henderson

“…Having mapped the processes required for the success of this initiative, there is now a requirement to assess its effect on health-related and quality of life outcomes as well as determining its cost-effectiveness. …”
Get full text

Correlations among fatigue, respiratory function, balance and core muscle morphology in multiple sclerosis: a comprehensive observational study by Marta De La Plaza San Frutos, Ismael Sanz-Esteban, Ismael Sanz-Esteban, Federico Salniccia, Federico Salniccia, Alberto Bermejo-Franco, Alberto Bermejo-Franco, Ameyalli García-Corona, María Cristina Palma-Baquedano, Marina Castel-Sánchez, Marina Castel-Sánchez, Cecilia Estrada-Barranco, Cecilia Estrada-Barranco

“…The strength and function of the central abdominal musculature, particularly the internal oblique, were crucial for trunk stability and postural control.ConclusionThese findings highlight the interplay between respiratory function, balance, fatigue, and abdominal muscle morphology in MS, emphasizing the potential benefits of interventions targeting respiratory function to improve balance and reduce fatigue, ultimately enhancing quality of life in this population.…”
Get full text

Utilization of Blood Flow Restriction Therapy with a Former Triathlete After Total Knee Arthroplasty: A Case Report by Christopher Keating, Stephanie Muth, Cameron Hui, Lisa T Hoglund

“…# Introduction and Purpose Knee osteoarthritis (OA) is a common condition that limits function and reduces quality of life. Total knee arthroplasty (TKA) is a surgical procedure that replaces the joint surfaces to address anatomical changes due to knee OA. …”
Get full text

Mixed methods evaluation of the Getting it Right First Time programme in elective orthopaedic surgery in England: an analysis from the National Joint Registry and Hospital Episode... by Stephen Morris, James Mason, Rosalind Raine, Peter Martin, Naomi J Fulop, Elena Pizzo, Andrew Hutchings, Helen Barratt, Jean Ledger, Raj Mehta, Sarah Jasim, Fiona Aspinal, Rafael Gafoor

“…Objective To evaluate the impact of the ‘Getting it Right First Time’ (GIRFT) national improvement programme in orthopaedics, which started in 2012.Design Mixed-methods study comprising statistical analysis of linked national datasets (National Joint Registry; Hospital Episode Statistics; Patient-Reported Outcomes); economic analysis and qualitative case studies in six National Health Service (NHS) Trusts.Setting NHS elective orthopaedic surgery in England.Participants 736 088 patients who underwent primary hip or knee replacement at 126 NHS Trusts between 1 April 2009 and 31 March 2018, plus 50 NHS staff.Intervention Improvement bundle including ‘deep dive’ visits by senior clinician to NHS Trusts, informed by bespoke set of routine performance data, to discuss how improvements could be made locally.Main outcome measures Number of procedures conducted by low volume surgeons; use of uncemented hip implants in patients >65; arthroscopy in year prior to knee replacement; hospital length of stay; emergency readmissions within 30 days; revision surgery within 1 year; health-related quality of life and functional status.Results National trends demonstrated substantial improvements beginning prior to GIRFT. …”
Get full text

HER-SAFE study design: an open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2-targeted therapy-related c... by Robin Chung, James C Moon, Alexander R Lyon, Charlotte H Manisty, Muhummad Sohaib Nazir, Malcolm Walker, Peter Kellman, Benjamin Dowsing, Daniel Chen, Jessica Artico, Mark Westwood, Hakim-Moulay Dehbi, Rebecca Roylance, Tom Crake, Peter Schmid, Arjun Ghosh, Maria Sol Andres, Joanna Pedra, Orla Worn

“…The need to continue HFT in ‘recovered’ HER2 CTRCD following completion of HER2 therapy is unclear and there are potential significant impacts on patient’s quality of life (QoL). The Randomised Controlled Trial for the Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction (HER-SAFE) aims to evaluate whether HFT can be safely withdrawn in non-high cardiovascular (CV) risk patients with ‘recovered’ HER2 CTRCD.Methods and analysis This is a multicentre, open-label randomised controlled trial investigating whether withdrawal of HFT is non-inferior to continuation in non-high CV risk, breast cancer survivors with recovered HER2 CTRCD after cancer treatment completion. …”
Get full text

Self-Management Strategies for Low Back Pain Among Horticulture Workers: Protocol for a Type II Hybrid Effectiveness-Implementation Study by Kim Dunleavy, Heidi Liss Radunovich, Jason M Beneciuk, Boyi Hu, Yang Yang, Janeen McCormick Blythe, Kelly K Gurka

“…If self-management is effective, mitigating pain positively impacts quality of life, productivity, and retention, while increasing the use of nonpharmacological alternatives to opioids addresses an important public health issue. …”
Get full text

Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial by Jelena Petković-Dabić, Ivana Binić, Bojana Carić, Ljiljana Božić, Sanja Umičević-Šipka, Nataša Bednarčuk, Saša Dabić, Mirna Šitum, Snježana Popović-Pejičić, Miloš P. Stojiljković, Ranko Škrbić

“…The results demonstrated that the severity of the clinical picture of psoriasis, determined by the Psoriasis Area and Severity Index (PASI) score, was significantly better after the administration of semaglutide (the median baseline PASI score in patients treated with semaglutide was 21 (IQR = 19.8), while after 12 weeks of therapy the score was 10 (IQR = 6; <i>p</i> = 0.002). Also, the quality of life in the group of patients who received the drug, measured by the Dermatology Life Quality Index (DLQI), improved significantly after 3 months (a median baseline DLQI score in the semaglutide group was 14 (IQR = 5) at the beginning of the study, and after 12 weeks of treatment the median DLQI score was 4 (IQR = 4; <i>p</i> = 0.002)). …”
Get full text

Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and i... by Sofia Ramiro, Désirée van der Heijde, Atul Deodhar, Xenofon Baraliakos, Denis Poddubnyy, Lianne S Gensler, Helena Marzo-Ortega, Natasha de Peyrecave, Victoria Navarro-Compán, Tetsuya Tomita, Carmen Fleurinck, Ute Massow, Thomas Vaux

“…Improvements in pain, fatigue, physical function and health-related quality of life were sustained.Conclusions The safety profile of bimekizumab after 5 years of treatment remained consistent with previous reports, with no new safety signals identified. 5-year efficacy was sustained in this r-axSpA population following robust disease control achieved at Week 48.Trial registration numbers NCT02963506; NCT03355573.…”
Get full text

Correlated factors of posttraumatic growth in patients with colorectal cancer: A systematic review and meta-analysis by Dingyuan Wei, Xue Wang, Mengxing Wang, Jiayan Wang, Fangping Chen, Luyang Jin, Xuemei Xian

“…Correlated factors were identified to be significantly associated with PTG in patients with CRC including demographic factors: residential area (r = 0.13), marital status (r = 0.10), employment status (r = 0.18), education level (r = 0.19), income level (r = 0.16); disease-related factors: time since surgery (r = 0.17), stoma-related complications (r = 0.14), health-promoting behavior (r = 0.46), and sexual function (r = 0.17); psychosocial factors: confrontation coping (r = 0.68), avoidance coping (r = −0.65), deliberate rumination (r = 0.56), social support (r = 0.47), family function (r = 0.50), resilience (r = 0.53), self-efficacy (r = 0.91), self-compassion (r = −0.32), psychosocial adjustment (r = 0.39), gratitude (r = 0.45), stigma (r = −0.65), self-perceived burden (r = −0.31), fear of cancer recurrence (r = −0.45); and quality of life (r = 0.32). Conclusions: This meta-analysis identified 23 factors associated with PTG in CRC patients. …”
Get full text

Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Ph... by Su H, Shang X, Liu H, Wang Y, Yu Y, Xu Y, Jiang K, Feng F

“…The secondary endpoints include objective response rate, duration of response, disease control rate, overall survival, toxicity and patients’ quality of life. Exploratory objectives aim to identify biomarkers and molecular signatures for predicting response or prognosis.Keywords: ovarian cancer, platinum-resistant, immune checkpoint inhibitor, lenvatinib, dose adjustment…”
Get full text

Computer‐Aided High Tibial Osteotomy—A Comparative Study of Commonly Used 3D Printing Technology and Navigation Application by Elvis Chun‐Sing Chui, Kyle Ka‐Kwan Mak, Randy Hin‐Ting Ng, Ericsson Chun‐Hai Fung, Mei‐Shuen Chan, Kai Yue, Lawrence Chun‐Man Lau, Clifford Long‐Fung Chan, Edmond Wing‐Fung Yau, Wei Zhao, Xiuyun Su, Jin Zhang, Jianglong Xu, Hongxun Sang, Guoxian Pei, Louis Wing‐Hoi Cheung, Sheung‐Wai Law, Michael Tim‐Yun Ong, Patrick Shu‐Hang Yung

“…And the results have implications for orthopedic surgeons performing HTO surgeries, as they can use this information to improve postoperative outcomes, such as mechanical axis alignment and quality of life for HTO patients.…”
Get full text

Ovarian cancer prevention through opportunistic salpingectomy during abdominal surgeries: A cost-effectiveness modeling study. by Angela Kather, Habib Arefian, Claus Schneider, Michael Hartmann, Ingo B Runnebaum

“…Setting costs for OS to €216.19 (calculated from average OS duration and operating room minute costs), implementation of OS would lead to healthcare cost savings as indicated by an ICER of €-8,685.50 per quality-adjusted life year (QALY) gained for strategy I, €-8,270.55/QALY for II, and €-4,511.86/QALY for III. …”
Get full text

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study by Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P. Maksymowych, Désirée van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Xenofon Baraliakos, Xianwei Bu, Ivan Lagunes-Galindo, In-Ho Song, Peter Wung, Koji Kato, Anna Shmagel

“…In patients who received continuous upadacitinib, sustained improvement was observed through 2 years of treatment across efficacy endpoints including disease activity, pain, function, enthesitis, quality of life, and MRI measures of inflammation. At week 104, 57.1%, 59.0%, and 31.4% of patients achieved ASAS40 response, and low disease activity and inactive disease (as defined by Axial Spondyloarthritis Disease Activity Score), respectively (AO-NRI); week 104 outcomes were generally similar in patients who initially received placebo and were switched to upadacitinib at week 52. …”
Get full text